Successful Tau Proteoform Assay Validation
The assay's reproducibility, accuracy, dynamic range, and sample compatibility aligned with launch specifications. Median percent error was approximately 10%, exceeding the target by a factor of three, and the median coefficient of variation was more than 15 times better than the target.
Cost Efficiency and Expense Reduction
Total operating expenses for Q1 2025 were $18.8 million, a 13% decrease compared to $21.6 million in Q1 2024. The reduction in expenses is due to cost efficiency and absence of nonrecurring costs from 2024.
Strong Cash Position
Nautilus ended the quarter with approximately $193 million in cash, cash equivalents, and investments, with a projected cash runway through 2027.
Positive Customer Feedback and Interest
Significant interest from proteomics researchers and potential partners in both targeted proteome and broad-scale discovery capabilities of Nautilus's platform.
Promising Alzheimer’s Disease Research
Early studies using the tau proteoform assay showed new insights into complex phosphorylation patterns in Alzheimer’s disease.